TABLE 3.
FIC testing of PT plus rifampin against clinical isolates
| Strain | MIC (µg · ml−1) |
FIC indexa | |||
|---|---|---|---|---|---|
| Alone |
Combination |
||||
| PTb | Rifampin | PT | Rifampin | ||
| P. aeruginosa | |||||
| PAO1 | 0.41 | 15.6 | 0.21 | 1.9 | 0.634 |
| RW01 | 0.41 | 15.6 | 0.13 | 1.9 | 0.439 |
| RW02 | 0.41 | 15.6 | 0.16 | 1.9 | 0.512 |
| RW03 | 0.51 | 15.6 | 0.16 | 3.9 | 0.564 |
| RW04 | 0.32 | 15.6 | 0.13 | 1.9 | 0.528 |
| RW05 | 0.32 | 31.25 | 0.13 | 1.9 | 0.467 |
| RW06 | 0.32 | 15.6 | 0.13 | 1.9 | 0.528 |
| RW07 | 0.32 | 15.6 | 0.13 | 1.9 | 0.528 |
| S. aureus | |||||
| UAMS-1 | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1110936 | 1.6 | 0.05 | 0.67 | 0.0035 | 0.489 |
| 1111063 | 2.1 | 0.1 | 0.67 | 0.0076 | 0.395 |
| 1071788 | 1.6 | 0.01 | 0.67 | 0.0015 | 0.569 |
| 1103430c | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1094094c | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1094140c | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1094147 | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1094166 | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1094178 | 2.1 | 0.1 | 0.67 | 0.0076 | 0.395 |
| 1144105c | 1.6 | 0.05 | 0.67 | 0.0035 | 0.489 |
| 1097612 | 2.1 | 0.05 | 0.67 | 0.0035 | 0.389 |
| 1097630 | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1122181c | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1122187c | 2.1 | 0.05 | 0.67 | 0.0035 | 0.389 |
| 1122190c | 1.6 | 0.05 | 0.67 | 0.0035 | 0.489 |
| 1122197c | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1132822c | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1101442c | 1.6 | 0.05 | 0.67 | 0.0035 | 0.489 |
| 1142776c | 2.1 | 0.01 | 0.67 | 0.0015 | 0.469 |
| 1125120c | 2.1 | 0.05 | 0.67 | 0.0076 | 0.471 |
| Vig R | 0.65 | 0.03 | 0.31 | 0.0078 | 0.75 |
FIC, fractional inhibitory concentration.
PT, polymyxin B-trimethoprim.
Methicillin-resistant Staphylococcus aureus (MRSA).